These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2923256)

  • 21. Central vasopressin pretreatment sensitizes phosphoinositol hydrolysis in the rat septum.
    Lebrun CJ; Gruber MG; Meister M; Unger T
    Brain Res; 1990 Oct; 531(1-2):167-72. PubMed ID: 1963099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intraventricular administration of arginine vasopressin suppresses prolactin release via a dopaminergic mechanism.
    DePaolo LV; Berardo PV; Carrillo AJ
    Peptides; 1986; 7(3):541-4. PubMed ID: 3774591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction between V1 and V2 effects in hemodynamic response to vasopressin in dogs.
    Liard JF
    Am J Physiol; 1990 Feb; 258(2 Pt 2):H482-9. PubMed ID: 2137987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypothalamic blood flow autoregulation remains unaltered following surgical and pharmacological blockade of central vasopressin.
    Sandor P; Petty M; de Jong W; Palkovits M; de Wied D
    Brain Res; 1991 Dec; 566(1-2):212-8. PubMed ID: 1814538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinetic actions and interactions of arginine vasopressin, angiotensin-II, and oxytocin on adrenocorticotropin secretion by rat anterior pituitary cells in the microperifusion system.
    Watanabe T; Oki Y; Orth DN
    Endocrinology; 1989 Oct; 125(4):1921-31. PubMed ID: 2551632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Studies of the nature of the interaction between vasopressin and corticotropin-releasing factor on adrenocorticotropin release in the rat.
    Rivier C; Rivier J; Mormede P; Vale W
    Endocrinology; 1984 Sep; 115(3):882-6. PubMed ID: 6086290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neonatal vasopressin antagonist treatment facilitates adult copulatory behavior in female rats and increases hypothalamic vasopressin content.
    Meyerson BJ; Höglund U; Johansson C; Blomqvist A; Ericson H
    Brain Res; 1988 Nov; 473(2):344-51. PubMed ID: 3233496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic cardiovascular effects of central vasopressin in conscious rats.
    Tsuchihashi T; Takata Y; Tomita Y; Takishita S; Nakao Y; Kobayashi K; Fujishima M
    Clin Exp Hypertens A; 1992; 14(4):699-716. PubMed ID: 1352744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antagonism of effects of vasopressin (AVP) on inhibitory avoidance by a vasopressin antagonist peptide [dPtyr(Me)AVP].
    LeBrun CJ; Rigter H; Martinez JL; Koob GF; Le Moal M; Bloom FE
    Life Sci; 1984 Oct; 35(14):1505-12. PubMed ID: 6482669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Central effects of endothelin-1 on vasopressin release, blood pressure, and renal solute excretion.
    Yamamoto T; Kimura T; Ota K; Shoji M; Inoue M; Sato K; Ohta M; Yoshinaga K
    Am J Physiol; 1992 Jun; 262(6 Pt 1):E856-62. PubMed ID: 1535483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histaminergic and catecholaminergic interactions in the central regulation of vasopressin and oxytocin secretion.
    Knigge U; Willems E; Kjaer A; Jørgensen H; Warberg J
    Endocrinology; 1999 Aug; 140(8):3713-9. PubMed ID: 10433231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxic effects of somatostatin in the cerebellum and vestibular nuclei: multiple sites of action.
    Balaban CD; Severs WB
    Neurosci Res; 1991 Oct; 12(1):140-50. PubMed ID: 1684238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Centrally administered interleukin-1 beta sensitizes to the central pressor action of angiotensin II.
    Ufnal M; Dudek M; Zera T; Szczepańska-Sadowska E
    Brain Res; 2006 Jul; 1100(1):64-72. PubMed ID: 16765325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of centrally administered vasopressin on orofacial pain perception in rats.
    Zubrzycka M; Janecka A
    Brain Res; 2005 Jul; 1051(1-2):112-6. PubMed ID: 15993385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of grooming behavior potencies of neurohypophyseal nonapeptides.
    Caldwell JD; Drago F; Prange AJ; Pedersen CA
    Regul Pept; 1986 May; 14(3):261-71. PubMed ID: 3014615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of beta-endorphin on arginine-8-vasopressin and oxytocin levels in rat brain areas.
    Vecsernyés M; Laczi F; Kovács GL; Szabó G; Janáky T; Telegdy G; László FA
    Experientia; 1989 May; 45(5):472-4. PubMed ID: 2524402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for a vasodilatory effect of vasopressin in the conscious rat.
    Walker BR
    Am J Physiol; 1986 Jul; 251(1 Pt 2):H34-9. PubMed ID: 3755295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemodynamic effects of neurohypophyseal peptides with antidiuretic activity in dogs.
    Schwartz J; Liard JF; Ott C; Cowley AW
    Am J Physiol; 1985 Nov; 249(5 Pt 2):H1001-8. PubMed ID: 3840655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered sensitivity to arginine vasopressin (AVP) in area CA1 of the hippocampal slice following pretreatment of rats with AVP.
    Burnard DM; Veale WL; Pittman QJ
    Brain Res; 1987 Sep; 422(1):11-6. PubMed ID: 3676773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emetic effects of centrally administered angiotensin II, arginine vasopressin and neurotensin in the dog.
    Wu M; Harding RK; Hugenholtz H; Kucharczyk J
    Peptides; 1985; 6 Suppl 1():173-5. PubMed ID: 4047979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.